Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1

Publication
Article
Supplements and Featured PublicationsTherapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1
Volume 1
Issue 1

This publication includes a summary of data on recent therapeutic advances in treating metastatic HER2-positive breast cancer that was presented during a series of 4 live regional broadcasts across the United States (California, Illinois, Texas, and Washington). Medical oncologists specializing in the treatment of breast cancer across those regions provide key insights on factors that influence planning and treatment selection.

Download Issue PDF
Articles in this issue
breast cancer
Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1
Related Videos
Samilia Obeng-Gyasi, MD, MPH,
Lauren E. Nye, MD
Debu Tripathy, MD
Nan Chen, MD
Debu Tripathy, MD
Timothy Yap, MBBS, PhD, FRCP
Parul N Barry, MD,
Ramez Kouzy, MD, MD Anderson
Elias Jabbour, MD
A panel of 4 experts on colorectal cancer
Related Content
Carlos Barrios, MD

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer

May 17th 2024
Article
D. Ross Camidge, MD, PhD; B.J. Rimel, MD, assistant professor, obstetrics and gynecology, Cedars-Sinai, medical director, Cancer Clinical Trials Office, Cedars-Sinai Cancer Institute, health sciences associate clinical professor, Department of Obstetrics and Gynecology, University of California, Los Angeles

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

April 15th 2024
Podcast
Sibylle Loibl, MD, PhD, chair, German Breast Group, chief executive officer, GBG Forschungs GmbH

Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer

May 17th 2024
Article
Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

April 11th 2024
Podcast
T-DXd in HER2+ Metastatic Breast Cancer | Image Credit: © Axel Kock - stock.adobe.com

T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer

May 16th 2024
Article
Mafalda Oliveira, MD, PhD

Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

May 16th 2024
Article